Strategic Vision for Growth
Byondis B.V., an independent biopharmaceutical company based in Nijmegen, The Netherlands, has appointed Christoph Korpus, PhD, MBA, as Chief Executive Officer, effective immediately. This announcement was made on 9 April 2026. Christoph has played a pivotal role in shaping the Company’s strategic transformation since his appointment as Chief Business Officer in January 2025.
Jacques Lemmens, PhD, the Founder of Byondis and Chairman of the Board of Directors, commented: "Since joining as CBO last year, Christoph has been instrumental in driving Byondis’ strategic transformation into a focused, fully-integrated biotech company with multiple proprietary ADC technology platforms and a wealth of clinical and manufacturing expertise."
In his new role, Korpus will guide the advancement of research and development activities for Byondis’ novel antibody-drug conjugate (ADC) technology platforms. These platforms include the cytotoxic antifolate linker-drug platform, ByonGuard™ masking technology for conditional activation, and ByonBoost™ immune-stimulatory linker-drug platform. Each has generated frontrunner and multiple follower drug candidates.
Korpus' Experience and Vision
Christoph Korpus brings over 15 years of experience in the biopharmaceutical industry, previously serving as Director of Global Business Development and Licensing Oncology at Merck KGaA. At Merck, he led partnering strategies and negotiation teams for multiple oncology transactions, managing global commercial and development alliances across various therapeutic areas.
Korpus holds a PhD from Ludwig-Maximilians-Universität Munich and the University of Connecticut, and an MBA from the Kellogg School of Management at Northwestern University and WHU-Otto Beisheim School of Management. His extensive experience in global business development and strategic partnerships, combined with a deep understanding of how Byondis’ platforms can address high unmet medical needs in oncology, makes him ideally suited to guide the company through its next phase of growth.
Byondis, with its fully integrated discovery, development, and manufacturing capabilities, has the flexibility to conduct all essential development efforts for its lead candidates independently. The company is open to partnerships around its pipeline assets and to licensing its technology for co-development opportunities.
The company remains committed to advancing its innovative oncology therapies and continues to seek partnerships and licensing opportunities for its pipeline assets. Under Korpus' leadership, Byondis aims to continue advancing its innovative pipeline to deliver breakthrough solutions for cancer patients.
